hTIGIT

Figure 1. Expression of human TIGIT in the polarized CD4+ T cells of humanized TIGIT mice is detected by FACS. Spleen Naive CD4+ T cells were isolated from heterozygous humanized TIGIT mice. After in vitro stimulation, activation and expansion by cytokines and antibodies, the CD4+ T cells were re-stimulated with PMA/ionomycin before the expression of human TIGIT in polarized CD4+ T cells was detected by FACS. The results showed that the active expression of human TIGIT could be detected in polarized CD4+ T cells collected from humanized TIGIT mice, and the expression trend of human TIGIT was similar to that of murine TIGIT.

Fig 2. In vivo validation of anti-tumor efficacy in a Hepa1-6 tumor-bearing model of humanized TIGIT mice. Homozygous humanized TIGIT mice were inoculated with Hepa1-6 cells. After the tumors grew to 110 mm3, the animals were randomly assigned into a control group and a treatment group. The results showed a significant anti-tumor effect was observed when the antibody targeting human TIGIT. (Completed in collaboration with CrownBio).

Fig 3. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized TIGIT mice. Homozygous humanized TIGIT mice were inoculated with MC38 colon cancer cells. After the tumors grew to 130 mm3, the animals were randomly assigned into a control group and a treatment group (n=7). The results showed a significant anti-tumor effect was observed when the antibody targeting human TIGIT was administered together with Anti-PD-L1 analogue. (Completed in collaboration with Harbour BioMed).